CXCR3 signaling in the TME was previously shown to be critical for the responsiveness of immunotherapy33, suggesting that CD169+ macrophages could be an attractive target for improving the success of immunotherapy treatments against gliomas. Here, SIGLEC1 is linked to glioma.